医学
膳食补充剂
随机对照试验
肝酶
糖尿病
内科学
临床试验
血甘油三酯
保健品
2型糖尿病
食品补充剂
内分泌学
胃肠病学
生物信息学
酶
药理学
血脂谱
脂肪变性
非诺贝特
脂质代谢
胰岛素抵抗
脂肪肝
人体研究
标识
DOI:10.20524/aog.2026.1019
摘要
Background: Despite its increasing prevalence, effective treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We assessed the efficacy of a dietary supplement containing dihydromyricetin (DHM) in MASLD. Methods: Adult MASLD patients were randomized to receive a dietary supplement containing DHM (300 mg/day), vitamins C/E and choline (group A), or identical placebo (group B) for 12 months. Patients were assessed every ≤6 months for clinical and laboratory parameters and liver stiffness measurements (LSM). Results: Fifty-five patients were randomized to group A (n=28) or B (n=27), but 9 patients (group A/B=2/7) were withdrawn early for personal reasons. Median liver enzymes decreased at 6 or 12 months only in group A. Group A compared to B patients achieved higher 12-month rates of combined alanine aminotransferase (ALT)/γ-glutamyl transpeptidase (GGT) normalization (35% vs. 5%, P=0.028). Only in group A, glucose, glycated hemoglobin and total/low density lipoprotein mean levels had declined significantly at 6 and/or 12 months, whereas median liver stiffness measurements (LSM) were lower than baseline at both 6 and 12 months. In multivariate analysis, group A was the only factor associated with ALT/GGT normalization (P=0.038). Generalized estimating equation analysis revealed a significant treatment by time interaction for 12-month combined ALT/GGT normalization only in group A (P=0.021). Conclusions: The 6/12-month use of DHM supplement seems to result in improvements in liver enzymes and LSM, as well as in diabetes and lipid parameters in MASLD patients. Therefore, the use of such a supplement in MASLD needs further evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI